immunomodulatory peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Second generation In the 1970s, the first technology was a model of prosthetic-breast with a shell of thin-gauge material and a filler-gel of low-cohesion silicone, which materials improved anatomic function and symmetry (size, appearance, texture) after contouring by the surgeon. In practise, second-generation breast prostheses proved fragile, with greater rates of shell-rupture and filler-leakage. The increased rates-of-incidence of capsular contracture consequently resulted in faulty-product class action-lawsuits by the U.S. government against the manufacturers of thin-gauge-shell breast prostheses. The second technology was a prosthetic breast with a polyurethane foam coating that reduced the rate of incidence of capsular contracture by causing an inflammatory reaction within the implant-socket in order to impede the formation of a capsule of fibrous collagen tissue around the prosthetic breast. In the event, the use of prosthetic breasts coated with polyurethane was discontinued in the U.S. because of the health risk posed by the carcinogenic chemical 2,4-toluene diamine (TDA), a by-product of the chemical breakdown of the polyurethane coating the prosthetic breast. Ultimately, prosthetic breasts coated with polyurethane remain in use in Europe and in South America. The third technology for breast surgery was the double-lumen prosthetic breast, which featured a lumen (a breast prosthesis filled with silicone-gel) contained within a larger lumen (a breast prosthesis filled with saline-solution).
Sarcosine, also known as N-methylglycine, or monomethylglycine, is a non-proteinogenic amino acid with the formula CH3N(H)CH2CO2H. It is the N-methyl derivative of glycine, with a secondary amine in place of the primary amine, and occurs naturally in muscles and other body tissues as an intermediate in the metabolism of choline to glycine. It was first isolated and named by the German chemist Justus von Liebig in 1847. Sarcosine is ubiquitous in biological materials. It is used in manufacturing biodegradable surfactants and toothpastes as well as in other applications. It is also a reagent in organic synthesis. It has a mildly sweet taste. Pharmacologically, sarcosine functions as a competitive inhibitor of the glycine transporter type 1 (GlyT1), a co-agonist at the glycine binding site of the NMDA receptor, and, at higher concentrations, an agonist at the strychnine-sensitive glycine receptor. These properties have led to its investigation as an adjunctive treatment in schizophrenia and major depressive disorder. Sarcosine has also been identified as an oncometabolite in prostate cancer, where elevated levels correlate with disease progression and metastatic potential.
=== Reconstitution === Perhaps the most extreme of treatments is "reconstitution", wherein fragments of fine turquoise material, too small to be used individually, are powdered and then bonded with resin to form a solid mass. Very often the material sold as "reconstituted turquoise" is artificial, with little or no natural stone, made entirely from resins and dyes. In the trade reconstituted turquoise is often called "block turquoise" or simply "block".
According to the nomenclature recommended by IUPAC, salts are named according to their composition, not their structure. In the most simple case of a binary salt with no possible ambiguity about the charges and thus the stoichiometry, the common name is written using two words. The name of the cation (the unmodified element name for monatomic cations) comes first, followed by the name of the anion. For example, MgCl2 is named magnesium chloride, and Na2SO4 is named sodium sulfate (SO2−4, sulfate, is an example of a polyatomic ion). To obtain the empirical formula from these names, the stoichiometry can be deduced from the charges on the ions, and the requirement of overall charge neutrality. If there are multiple different cations and/or anions, multiplicative prefixes (di-, tri-, tetra-, ...) are often required to indicate the relative compositions, and cations then anions are listed in alphabetical order. For example, KMgCl3 is named magnesium potassium trichloride to distinguish it from K2MgCl4, magnesium dipotassium tetrachloride (note that in both the empirical formula and the written name, the cations appear in alphabetical order, but the order varies between them because the symbol for potassium is K). When one of the ions already has a multiplicative prefix within its name, the alternate multiplicative prefixes (bis-, tris-, tetrakis-, ...) are used. For example, Ba(BrF4)2 is named barium bis(tetrafluoridobromate).
=== Reconstituted Transitional National Legislative Assembly (2021–present) === As a result of a 2018 peace agreement that came into effect in February 2020, a Reconstituted Transitional National Legislative Assembly with 550 members was nominated in May 2021. The membership is as follows:
Sources: en.wikipedia.org
== Reactive Histiocytosis == Systemic Histiocytosis (SH) was originally recognized in closely related Bernese Mountain Dogs. SH is a generalized histiocytic proliferative disease with a marked tendency to involve skin, ocular and nasal mucosa, and peripheral lymph nodes. The disease predominately affects young to middle aged male dogs (2–8 years), although cases in females have been observed. SH has been observed in other breeds less commonly (e.g. Irish Wolfhounds, Basset Hounds and others). Clinical signs vary with the severity and extent of the disease and include anorexia, marked weight loss, stertorous respiration and conjunctivitis with marked chemosis. Multiple cutaneous nodules may be distributed over the entire body, but are especially prevalent in the scrotum, nasal apex, nasal planum and eyelids. Peripheral lymph nodes are often palpably enlarged. The disease course may be punctuated by remissions and relapses, which may occur spontaneously especially early in the disease course. In severe disease, lesions become persistent and do not respond to immunosuppressive doses of corticosteroids. Cutaneous histiocytosis (CH) is a histiocytic proliferative disorder that primarily involves skin and subcutis and does not extend beyond the local draining lymph nodes. CH occurs in a number of breeds. Evidence of spread beyond the skin would invoke the diagnosis of SH, a closely related disorder. Lymphadenopathy has not been emphasized in published reports, and has only been documented in a small number of our cases.
Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal. Many of the older designer drugs (research chemicals) are structural analogues of psychoactive tryptamines or phenethylamines but there are many other chemically unrelated new psychoactive substances that can be considered part of the designer drug group. Designer drugs can also include substances that are not psychoactive in effect, such as analogues of controlled anabolic steroids and other performance and image enhancing drugs (PIEDs), including nootropics, weight loss drugs and erectile dysfunction medications. The pharmaceutical activities of these compounds might not be predictable based strictly upon structural examination. Many of the substances have common effects while structurally different or different effects while structurally similar due to SAR paradox. As a result of no real official naming for some of these compounds, as well as regional naming, this can all lead to potentially hazardous mix ups for users. The following list is not exhaustive.
===== Third and fourth generations ===== In the 1980s, the models of the third and of the fourth generations of breast implant devices were sequential advances in manufacturing technology, such as elastomer-coated shells that decreased gel-bleed (filler leakage), and a thicker (increased-cohesion) filler gel. Sociologically, the manufacturers of prosthetic breasts then designed and made anatomic models (natural breast) and shaped models (round, tapered) that realistically corresponded with the breast- and body- types of women. The tapered models of breast implant have a uniformly textured surface, which reduces the rotation of the prosthesis within the implant pocket; the round models of breast implant are available in smooth-surface- and textured-surface- types.
ADP + a phosphoprotein Thus, the two substrates of this enzyme are ATP and a protein, whereas its two products are ADP and phosphoprotein. The systematic name of this enzyme class is ATP:protein phosphotransferase (non-specific).
Sources: en.wikipedia.org
Geranylgeraniol 18-hydroxylase is a cytochrome P450 protein containing heme, isolated from Croton sublyratus. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
=== Lifestyle modification === For some people with hypermobility, lifestyle changes decrease symptom severity. Regular movement is recommended, and support devices can be used. These include shaped keyboards to assist posture, insoles to support flat feet, and wide grip pens. Pillows and cushions can be used to support joints.
Amino acids are a set of organic compounds that are used by living organisms to synthesise proteins. All amino acids (except glycine) have one or more pairs of stereoisomers, isomers which share the same bond order but are organized differently in 3D space. A given pair of stereoisomers that are optically active and non-superimposable mirror images of each other are called enantiomers; pairs that are not mirror images are diastereomers or epimers. Stereoisomers of the same molecule may undergo reactions (known as racemization or epimerization respective to the type of stereoisomer pair involved) that convert them to other stereoisomers. Biological systems are stereoselective, preferring certain stereoisomers for chemical reactions; living organisms keep all their amino acids in their "left-handed" (L or levo-) forms (a state called homochirality) because they are unable to use the "right-handed" (D or dextro-) forms for protein synthesis. When an organism becomes unable to keep its amino acids in that unbalanced ratio, such as by dying or shedding tissue, the system will proceed towards chemical equilibrium. Measuring the progress of this interconversion reaction allows estimation of an organism's time of death, if environmental variables like moisture and temperature are accounted for.
Feathers are one of the most recognizable characteristics of modern birds, and a trait that was also shared by several non-avian dinosaurs. Based on the current distribution of fossil evidence, it appears that feathers were an ancestral dinosaurian trait, though one that may have been selectively lost in some species. Direct fossil evidence of feathers or feather-like structures has been discovered in a diverse array of species in many non-avian dinosaur groups, both among saurischians and ornithischians. Simple, branched, feather-like structures are known from heterodontosaurids, primitive neornithischians, and theropods, and primitive ceratopsians. Evidence for true, vaned feathers similar to the flight feathers of modern birds has been found only in the theropod subgroup Maniraptora, which includes oviraptorosaurs, troodontids, dromaeosaurids, and birds. Feather-like structures known as pycnofibres have also been found in pterosaurs. However, researchers do not agree on whether these structures share a common origin between lineages (i.e., they are homologous), or if they were the result of widespread experimentation with skin coverings among ornithodirans. If the former is the case, filaments may have been common in the ornithodiran lineage and evolved before the appearance of dinosaurs themselves. Research into the genetics of American alligators has revealed that crocodylian scutes do possess feather-keratins during embryonic development, but these keratins are not expressed by the animals before hatching.
=== Christmas Island Phosphate Company === The first European to recommend mining of phosphate for commercial exploitation was Sir John Murray, a British naturalist, during the 1872–76 Challenger expedition. His discovery led to annexation of the island by the British Crown on 6 June 1888. In 1900 the Pacific Islands Company Ltd commenced mining on Ocean Island, with 1550 tons shipped from September to December 1901 and 13,350 tons in the following year. John T. Arundel and Lord Stanmore, directors of PIC, were responsible for financing the new opportunities and negotiating with the German company that controlled the licences to mine in Nauru. In 1902 the interests of PIC were merged with Jaluit Gesellschaft of Hamburg, to form the Pacific Phosphate Company Ltd (PPC), to engage in phosphate mining in Nauru and Ocean Island.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.